论文部分内容阅读
目的探讨重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白对严重脓毒血症患者细胞因子的影响。方法将42例严重脓毒血症患者随机分为对照组和治疗组,其中对照组17例,治疗组25例,两组均行常规抗感染和病因治疗。治疗组用1毫升注射用水溶解50 mg重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白,皮下注射,隔日一次;分别于治疗前、注射后7天后测试ss-CRP及TNF-α。结果与对照组相比,治疗组应用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白后ss-CRP及TNF-α均明显降低,P<0.05。结论重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白可降低严重脓毒血症患者TNF-α的水平,从而达到保护器官的作用。
Objective To investigate the effect of recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein on cytokines in patients with severe sepsis. Methods Forty-two patients with severe sepsis were randomly divided into control group and treatment group, 17 cases in control group and 25 cases in treatment group. Conventional anti-infective and etiological treatment were performed in both groups. In the treatment group, 50 mg recombinant human type II tumor necrosis factor receptor-antibody fusion protein was dissolved in 1 ml of water for injection and injected subcutaneously once every other day. The levels of ss-CRP and TNF-α were measured before treatment and 7 days after injection respectively. Results Compared with the control group, the levels of ss-CRP and TNF-α in the treated group were significantly decreased (P <0.05) after the recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein was used. Conclusion Recombinant Human Tumor Necrosis Factor Receptor-Antibody Fusion Protein Type 2 can reduce the level of TNF-α in patients with severe sepsis and thus protect the organs.